HUE054247T2 - Kombináció, amely egy aminotiol-észter-vegyületet vagy ennek gyógyszerészetileg elfogadható sóját, valamint egy egyed rákos sejtjeiben a H2O2 szint emelésére alkalmas vegyületet tartalmaz - Google Patents

Kombináció, amely egy aminotiol-észter-vegyületet vagy ennek gyógyszerészetileg elfogadható sóját, valamint egy egyed rákos sejtjeiben a H2O2 szint emelésére alkalmas vegyületet tartalmaz

Info

Publication number
HUE054247T2
HUE054247T2 HUE16784442A HUE16784442A HUE054247T2 HU E054247 T2 HUE054247 T2 HU E054247T2 HU E16784442 A HUE16784442 A HU E16784442A HU E16784442 A HUE16784442 A HU E16784442A HU E054247 T2 HUE054247 T2 HU E054247T2
Authority
HU
Hungary
Prior art keywords
raising
levels
individual
combination
pharmaceutically acceptable
Prior art date
Application number
HUE16784442A
Other languages
English (en)
Hungarian (hu)
Inventor
Ismail Ceylan
Gerry Quash
Mileidys Perez-Alea
Guillaume Martin
Original Assignee
Advanced Biodesign
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biodesign filed Critical Advanced Biodesign
Publication of HUE054247T2 publication Critical patent/HUE054247T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE16784442A 2015-10-15 2016-10-14 Kombináció, amely egy aminotiol-észter-vegyületet vagy ennek gyógyszerészetileg elfogadható sóját, valamint egy egyed rákos sejtjeiben a H2O2 szint emelésére alkalmas vegyületet tartalmaz HUE054247T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15306650 2015-10-15

Publications (1)

Publication Number Publication Date
HUE054247T2 true HUE054247T2 (hu) 2021-08-30

Family

ID=54360386

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16784442A HUE054247T2 (hu) 2015-10-15 2016-10-14 Kombináció, amely egy aminotiol-észter-vegyületet vagy ennek gyógyszerészetileg elfogadható sóját, valamint egy egyed rákos sejtjeiben a H2O2 szint emelésére alkalmas vegyületet tartalmaz

Country Status (21)

Country Link
US (1) US10406125B2 (cg-RX-API-DMAC10.html)
EP (1) EP3362094B1 (cg-RX-API-DMAC10.html)
JP (1) JP7062592B2 (cg-RX-API-DMAC10.html)
CN (1) CN108348612A (cg-RX-API-DMAC10.html)
AR (1) AR106351A1 (cg-RX-API-DMAC10.html)
CA (1) CA3001201C (cg-RX-API-DMAC10.html)
CY (1) CY1123916T1 (cg-RX-API-DMAC10.html)
DK (1) DK3362094T3 (cg-RX-API-DMAC10.html)
ES (1) ES2870508T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20210358T1 (cg-RX-API-DMAC10.html)
HU (1) HUE054247T2 (cg-RX-API-DMAC10.html)
IL (1) IL258658B (cg-RX-API-DMAC10.html)
LT (1) LT3362094T (cg-RX-API-DMAC10.html)
MX (1) MX377725B (cg-RX-API-DMAC10.html)
PL (1) PL3362094T3 (cg-RX-API-DMAC10.html)
PT (1) PT3362094T (cg-RX-API-DMAC10.html)
RS (1) RS61572B1 (cg-RX-API-DMAC10.html)
SI (1) SI3362094T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202100270T1 (cg-RX-API-DMAC10.html)
WO (1) WO2017064241A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201802400B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102941434B1 (ko) * 2019-07-31 2026-03-19 어드방스드 비오디자인 아미노티올에스터 화합물 및 이의 용도
FR3119314B1 (fr) * 2021-01-29 2025-01-10 Advanced Biodesign Nanocapsule lipidique comprenant au moins un composé aminothiolester ou un de ses dérivés pharmaceutiquement acceptable
EP4035666A1 (en) * 2021-01-29 2022-08-03 Advanced Biodesign Aminothiolester compound or derivative thereof for use as an immunomodulatory agent
WO2025229179A1 (en) * 2024-05-03 2025-11-06 Advanced Biodesign Use of aminothiolester compounds in combination with hypomethylating agents (hma) for the prevention and treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
FR2809727B1 (fr) * 2000-05-31 2002-07-26 Galderma Res & Dev Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations

Also Published As

Publication number Publication date
RS61572B1 (sr) 2021-04-29
IL258658A (en) 2018-06-28
US10406125B2 (en) 2019-09-10
WO2017064241A1 (en) 2017-04-20
MX377725B (es) 2025-03-11
HK1251477A1 (en) 2019-02-01
JP2018531995A (ja) 2018-11-01
DK3362094T3 (da) 2021-03-01
HRP20210358T1 (hr) 2021-04-16
SI3362094T1 (sl) 2021-04-30
LT3362094T (lt) 2021-05-10
CN108348612A (zh) 2018-07-31
JP7062592B2 (ja) 2022-05-06
EP3362094A1 (en) 2018-08-22
IL258658B (en) 2021-04-29
CY1123916T1 (el) 2022-05-27
CA3001201C (en) 2023-07-11
PT3362094T (pt) 2021-04-15
AR106351A1 (es) 2018-01-03
PL3362094T3 (pl) 2021-10-11
SMT202100270T1 (it) 2021-07-12
MX2018004381A (es) 2018-05-11
ES2870508T3 (es) 2021-10-27
US20180303773A1 (en) 2018-10-25
BR112018007480A2 (en) 2018-10-23
CA3001201A1 (en) 2017-04-20
EP3362094B1 (en) 2021-02-17
ZA201802400B (en) 2020-01-29

Similar Documents

Publication Publication Date Title
FIC20260007I1 (fi) Vimseltinibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
EP3615008A4 (en) ORAL HSP90 INHIBITOR FORMULATIONS AND RELATED PROCESSES
EP3423112A4 (en) HSP9 INHIBITOR-ACTIVE CONJUGATES
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
EP3250080A4 (en) Oral care implement
IL276952A (en) History of 4,2-diaminoquinazolines and their medicinal uses
EP3655558A4 (en) CUSTOM TITANIUM ALLOY, TI-64, 23+
EP3556368A4 (en) THERAPEUTIC FOR ONYCHOMYCOSIS
IL286434A (en) Nicoandyl derivatives
EP3331583B8 (en) Medical implant based on nanocellulose
EP3478359A4 (en) BIOINSPIRED FAST FITTING OF COCHLEAIM PLANTATES
IL258658B (en) Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject
IL282999A (en) 1,3,4-oxadiazolone compound and pharmaceutical
EP3851070A4 (en) IMPLANT STRUCTURE
EP3916116A4 (en) MEDICAL AU-PT-PD ALLOY
SG11202103806VA (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
HUE053725T2 (hu) Aminotiolészter vegyületek vagy azok gyógyászatilag elfogadható sói, rák kezelésében történõ alkalmazásra
IL274868A (en) History of imidazopyridine and their use as medicine
HK1243709A1 (zh) 可用於治疗阿尔茨海默氏病的四氢呋喃稠合的氨基氢噻嗪衍生物
ZA201804275B (en) Oral pharmaceutical composition comprising taste-masked n-acetylcysteine
EP3278806A4 (en) Glucose-sensitive cell protecting agent
IL279131A (en) CLN5 optimized genes and expression cassettes and their use
HK40044874A (zh) 2,4-二氨基喹唑啉衍生物及其医学用途
FIC20190056I1 (fi) talatsoparibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
GB201902087D0 (en) Medicament and the use thereof